Institut fuer Atemwegsforschung GmbH, Wiesbaden, Germany Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2018
NCT03590379
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Institut fuer Atemwegsforschung GmbH, Wiesbaden, Germany

Active Ingredients

Drugs in Phase 2 Trials (2)

budesonide (rhinocort) (1 trial)

formoterol (foradil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2